Mode
Text Size
Log in / Sign up
N/A N=149 Randomized Single-blind Treatment

Comparison Study of Surgical Staplers for the Treatment of Hemorrhoids

Hemorrhoids

Enrolled (actual)
149
Serious AEs
3.4%
Results posted
Oct 2014
Primary outcome: Primary: Intraoperative Bleeding — 32; 50 participants — p=0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
EEA Hemorrhoid and Prolapse Stapling Set (Device); Endosurgery Proximate PPH03 Stapling Set (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medtronic - MITG
Primary completion
Aug 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Intraoperative Bleeding
32; 50 0.0001 sig
SECONDARY
Post Operative Pain - (PI-NIRS)
2.0; 2.1; 1.0; 0.8; 0.5; 0.3
SECONDARY
Post-Operative Pain (Analgesic Intake)
37; 25; 29; 18; 14; 15
SECONDARY
Overall Quality of Life - General Health Score
53.89; 54.58; -0.26; -2.13; 0.44; -1.05
SECONDARY
Location of the Staple Line
25.94; 24.00 0.1844
SECONDARY
Length of Stay
4.16; 4.37 0.5647
SECONDARY
Operative Room (OR) Time
25.4; 25.6 0.9062

Summary

The purpose of this study is to demonstrate that the Covidien EEA™ Hemorrhoid and Prolapse Stapling Set for the treatment of hemorrhoids is non-inferior to the competitor device based on the primary endpoint.

Eligibility Criteria

Inclusion Criteria

  • The subject is able to understand and sign Informed Consent Form
  • The subject is between 18-85 years of age.
  • The subject has (symptomatic) Grade 2-3 Hemorrhoids and is eligible for stapled hemorrhoidopexy

Exclusion Criteria

  • The procedure is needed as revision hemorrhoid surgery.
  • Any female patient, who is pregnant, suspected pregnant, or nursing.
  • The participant has an active or a history of infection requiring antibiotics at the intended operative site within thirty (30) days prior to the planned surgery date.
  • The participant is unable or unwilling to comply with the study requirements, follow-up schedule.
  • The participant has a 1 year history of drug or alcohol abuse.
  • The participant has a history of venous thrombosis or pulmonary embolism.
  • The participant has a history of coagulopathy.
  • The participant has taken aspirin, anti-coagulation and/or anti platelet therapies (e.g. Warfarin, Lovenox) within 7 days prior to the planned date of surgery.
  • The participant has a history of fecal incontinence
  • The participant has had injection therapy, infrared laser treatment or rubber band ligation for treatment of hemorrhoids within 1 month of screening
  • The participant has co-morbidities which, in the opinion of the investigator, will not be appropriate for the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01306877). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search